SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”, or the “Company”, or “SBC”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced a business alliance with MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) ("MEDIROM"), a rapidly growing company in the healthcare technology field with over 300 relaxation studios in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241103701498/en/
SBC Medical Group Holdings Incorporated, a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced a business alliance with MEDIROM Healthcare Technologies Inc., a rapidly growing company in the healthcare technology field. (Graphic: Business Wire)
SBC Medical and MEDIROM, two trusted beauty and wellness leaders that excel in customer-centric experiences, together will create a new way for beauty and wellness enthusiasts to discover exciting and new health treatments. The alliance brings together MEDIROM’s leading brand of relaxation salons and health-related product and service offerings with SBC’s best-in-class cosmetic treatment centers that today serve millions of customers who love the ease, convenience, and value of SBC’s experience.
Together, the two leading healthcare service providers have more than 4 million members across their loyalty programs at SBC’s “Shonan Beauty Clinic” and MEDIROM’s Re.Ra.Ku. In addition to bringing customers enhanced offerings and expertise, the alliance will seek to create compelling, integrated opportunities to harness the power of these loyal customers and reward them when they receive services at SBC Medical and MEDIROM.
Background of Alliance
Based on the concept of " Ultimate Win-Win for All " SBC Medical Group provides management support services to a wide range of medical institutions, including comprehensive cosmetic medicine, dentistry, AGA treatment, gynecology, infertility treatment, ophthalmology, plastic surgery, and regenerative medicine. The Company’s network of clinics, including “Shoan Beauty Clinic”, now numbers 224 worldwide. MEDIROM, under the brand name “Re.Ra.Ku”, operates more than 300 relaxation studios in Japan based on the concept of "health, more, and more innovative," and is developing a diversified business centered on healthcare. The company also focuses on health maintenance and preventive medicine, and continues to innovate in this industry.
Reaching new customers and creation of synergies
In this alliance, both companies have elevated expectations for their different customer segments. Shonan Beauty Clinic is widely supported mainly by women in their 20s and 30s, while MEDIROM's Re.Ra.Ku serves mainly male customers for relaxation and health maintenance. This collaboration is expected to enable the two companies to approach new markets, expand our total customer base, and provide new value. As a first step, during the period from November 15, 2024 to December 15, 2024, customers visiting Shonan Beauty Clinic will receive special invitation tickets to experience Re.Ra.Ku at a discounted price. The two companies plan to continue to deepen their collaboration in stages, aiming to provide new value oriented experiences that offer total support for beauty and health.
Initial Co-Marketing Campaign
Customers visiting Shonan Beauty Clinic and Re.Ra.Ku will receive special invitation tickets for a limited time.
Participating Clinics and Stores
Shonan Beauty Clinic: 130 clinics
Re.Ra.Ku (directly managed stores): 230 stores
Distribution period
Shonan Beauty Clinic: Friday, November 15, 2024 - Sunday, December 15, 2024
Re.Ra.Ku: Sunday, December 1, 2024 - Monday, January 13, 2025
About MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc., together with its subsidiaries, provides holistic health services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The Relaxation Salon segment owns, develops, operates, franchises, and supports relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology.
About SBC Medical
SBC Medical, through its subsidiaries, provides services to support the operation of clinics that deliver highly specialized medical services in the areas of cosmetic medicine, esthetic dentistry, and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical and its subsidiaries now provide management services to a total of 224 franchisees located worldwide. For Global, SBC Medical owns and operates one treatment center in Vietnam and provides management services to one treatment center in State of California in the United States. For more information, visit https://sbc-holdings.com/
Forward Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” and elsewhere in the proxy statement and other materials filed with the U.S. Securities and Exchange Commission. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether because of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a total risk of loss.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241103701498/en/
Contacts
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
e-mail: ir@sbc-holdings.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom